Stock on Focus: Biogen Inc. (BIIB)

Company Profile:

Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Recent News:

The company will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open. Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am ET.

The company reported 2016 total revenues of $11.4 billion, a 6% increase versus the prior year. On a constant currency basis1, total revenues grew 9%.

On April 13, 2017, the company announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP), from Bristol-Myers Squibb (BMY).


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



BIIB’s strengths can be seen in its better growth, strong profitability, better solvency and better efficiency compared with its peers. Its revenue and net income have increased over several years. Technical indicators signal the bullish signs, as MACD goes green, there is a bullish cross in Stochastic Oscillator and RSI stands at 43.42 with positive bias. We rate Biogen Inc. (BIIB) a STRONG BUY.

About the Author

has written 9991 stories on this site.

Copyright © 2012 Nine Stocks